Navigation Links
Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Date:1/10/2013

Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer, not only can genes themselves go bad, but abnormal changes in the epigenetic mixing board can unfortunately change the expression of these genes. Researchers hope to play the role of sound engineers, controlling these harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs.

The epigenome's primary tool and by far the easiest to study is methylation: it attaches little methyl groups to DNA sequences near the genes to silence or promote their expression.

"Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says Subhajyoti De, PhD, CU Cancer Center investigator and assistant professor at the CU School of Medicine.

In other words, methylation patterns predict patient survival. Here's how it works:

DNA should be methylated in a consistent way you get a certain, standardized amount of methyl "residue" attached to your genes. Sure enough, that's the case in healthy B-cells. Subhajyoti and colleagues show that in cancerous B-cells, the level of DNA methylation from cell to cell varies wildly. And the more wildly the level of DNA methylation varies, the more aggressive is the cancer. It's as if, in the body, you want a consistent epigenome that maintains the methylation of the healthy status quo when a willy-nilly epigenome drops methylation randomly here and there, it promotes non-normal cells, like cancer.

So abnormal methylation is certainly correlated with not only cancer, but with the aggressive behaviors of cancer subtypes. But what exactly is the functional role of this methylation?

"We think that in addition to genetic mutations that cause cancer, epigenetic changes probably play a subtle role that allows the cancer to thrive within our body," Subhajyoti says.

There are drugs that affect the epigenome's ability to methylate and so control genes some of which crescendo or decrescendo the amount of methylation across the board, and some of which affect the amount of methylation on certain genetic products. Does one of these drugs hold the key to muting cancer?

Subhajyoti hopes to find out.

"For the last 50 years, the scientific community pushed to identify the genetic drivers of cancer, but now in the past five or six years we've expanded the search into the epigenome as well," Subhajyoti says. "We now expect to find that both genetic and epigenetic abnormalities are important for initiation and maintenance of cancer."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Epilepsy Leads to More Brain Abnormalities Over Time
2. Insecticide Linked to Brain Abnormalities in Kids
3. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
4. Treatment of childhood OSA reverses brain abnormalities
5. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
6. Gene Mutation Linked to Facial, Skull Abnormalities
7. Brain Scans of Hoarders Show Unique Abnormalities
8. Documenting womens experiences with chromosome abnormalities found in new prenatal test
9. Psychological testing may predict success in soccer
10. Predictors identified for rehospitalization among post-acute stroke patients
11. Can a standard vision test predict nighttime driving performance?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Texas (PRWEB) , ... June 20, 2017 , ... HOUSTON ... their new website and a host of new options for today’s modern senior. ... seniors maintain the active, independent lifestyle they love while offering them the services to ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju ... OH for leading-edge care, whether or not they have a referral. Dr. Kejriwal ... WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding ...
(Date:6/20/2017)... Boston, MA (PRWEB) , ... June 20, 2017 ... ... Innovation’s (IPI) Clinical Innovation Catalyst program focused on finding product improvements ... have tubes placed in their throats when they need help breathing or to ...
(Date:6/20/2017)... NY (PRWEB) , ... June 20, 2017 , ... ... in the security systems industry has been selected as the partner of choice ... is a passenger railroad service that provides medium- and long-distance intercity service in ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... bedside, would like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN ... whose insight and expertise in healthcare will provide invaluable direction for the company,” ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:5/30/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... that it will be presenting at the 7th annual LD Micro ... Erez Raphael , CEO, of DarioHealth will be giving the presentation ... on June 6th & 7th, 2017 at the Luxe Sunset Bel ... micro-cap space. About LD Micro ...
Breaking Medicine Technology: